Premium
P1‐303: White Matter Changes to The Therapeutic Outcome in Alzheimer’s Disease
Author(s) -
Yang Yuan-Han
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1053
Subject(s) - rivastigmine , medicine , clinical dementia rating , white matter , dementia , stage (stratigraphy) , alzheimer's disease , rating scale , disease , hyperintensity , mini–mental state examination , donepezil , magnetic resonance imaging , psychology , radiology , paleontology , developmental psychology , biology
showing increased atrophy. The effects were amplified when FSH or LH moderation was assessed, and strongly reversed for testosterone (Fig. 3). Higher testosterone showed significantly reduced MCIrelated degeneration in dorsomedial and anterior thalamus, putamen, left amygdala and nucleus accumbens. FSH and LH (not shown) had similar effects with accelerated atrophy. Higher critical p-values (Pc) in each figure indicate more widespread effect. Conclusions:These results indicate that sex differences in AD progression may be related to FSH and Testosterone levels. Atrophy in the dopaminergic striatal regions may be mediated by the FSH-testosterone feedback loop. As the dorsomedial and anterior thalamic nuclei have been implicated in sleep, their associations with testosterone levels helps explain early sleep disturbances associated with AD onset. This study suggests the use of imaging to determine the benefit of hormone levels and HRT on neurodegeneration. P1-303 WHITE MATTER CHANGES TO THE THERAPEUTIC OUTCOME IN ALZHEIMER’S DISEASE